Bottom line
Is RYSGX a good fund? The bottom line
RYSGX is the Class A share class of S&P SmallCap 600 Pure Growth Fund, an actively managed small-cap mutual fund from Guggenheim.
Its expense ratio is 1.53% — about $153 a year on every $10,000 invested, more expensive than 87% of small-cap funds we track.
It returned +3.4% over one year, +1.9% a year over five years, +6.1% a year over ten (as of Dec 31, 2025, per its prospectus).
With $60.7 million in net assets and 129 holdings, its largest position is Acm Research Inc (3.8%) and the top 10 make up 19.1% of the portfolio.
This share class carries a front-end sales charge of up to 4.75%; a no-load class or ETF alternative can avoid it.
What to watch
- Expensive for its category (1.53%)
- 5-year return in the bottom quarter of its category
- Front-end sales load up to 4.75%
- 12b-1 marketing fee of 0.25% a year
- High turnover (1,133% a year) can mean more taxable distributions
Updated Nov 19, 2026
What RYSGX invests in
The S&P SmallCap 600 Pure Growth Fund (the Fund) seeks to provide investment results that match, before fees and expenses, the performance of a benchmark for small-cap growth securities on a daily basis. The Funds current benchmark is the S&P SmallCap 600 Pure Growth Index (the underlying index).
The Fund employs as its investment strategy a program of investing in the common stock of companies that are generally within the capitalization range of the underlying index and derivative instruments, which primarily consist of equity index swaps, futures contracts, and options on securities, futures contracts, and stock indices. While the Fund may write (sell) and purchase swaps, it expects primarily to purchase swaps. Equity index swaps and futures and options contracts enable the Fund to pursue its investment objective without investing directly in the securities included in the underlying index or in the same proportion that those securities are represented in the underlying index. Certain of the Funds derivatives investments may be traded in the over-the-counter (OTC) market. Under normal circumstances, the Fund will invest at least 80% of its net assets, plus any borrowings for…
From the fund's prospectus (filed Jul 29, 2026).
RYSGX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| RYSGX | +3.4% | +1.9% | +6.1% |
| Small-Cap median | +7.6% | +7.0% | +9.2% |
Source: Fund prospectus, as of Dec 31, 2025
What RYSGX costs
On a $10,000 investment, RYSGX's 1.53% expense ratio costs about $153 a year. The prospectus estimates $2,260 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.
RYSGX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Acm Research Inc ACMR | 3.80% |
| 2 | Powell Industries Inc POWL | 2.05% |
| 3 | Argan Inc AGX | 2.04% |
| 4 | Dave Inc DAVE | 1.85% |
| 5 | Stonex Group Inc SNEX | 1.66% |
| 6 | Protagonist Therapeutics Inc PTGX | 1.59% |
| 7 | Sphere Entertainment Company SPHR | 1.56% |
| 8 | Clear Secure Inc YOU | 1.54% |
| 9 | Alignment Healthcare Inc ALHC | 1.53% |
| 10 | Liquidia Corp LQDA | 1.51% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 19.1% of the fund. See all top 25 holdings and asset mix →